Record diabetes product revenue of $0.8M Progress with over-the-counter wearable device to treat chronic pain DPNCheck ® launch in Japan Overall year-over-year revenue growth of 9% WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), today reported business
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today said it plans to
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), today reported publication of results from a DPNCheck ® study conducted at the Diabetes Research Unit of the Ipswich Hospital NHS Trust in the United Kingdom . The study by Sharma and colleagues titled "Assessment of Diabetic
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), today announced that Shai N. Gozani M.D ., Ph.D., NeuroMetrix President and Chief Executive Officer, will participate in the 29 th Annual Meeting of The Japan Society of Diabetic Complications to be held in Tokyo on October 3 and
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), today announced that it has appointed Frank McGillin as Senior Vice President and General Manager, Consumer. Mr. McGillin will be responsible for development of a consumer healthcare business built on the Company's wearable
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today announced that Shai N.
Record number of SENSUS™ devices sold FDA regulatory clearance for over-the-counter wearable technology to treat chronic pain DPNCheck ® regulatory approval in Japan Year-over-year revenue growth of 16% $8.0 million new capital to support commercial and R&D initiatives WALTHAM, Mass.
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ: NURO) reported today that it had reached the 10th anniversary of its initial listing on NASDAQ. NeuroMetrix debuted on NASDAQ on July 22, 2004 as a medical device company with unique technology that allowed nerve conduction studies,
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today said it plans to
Key Step Towards Entering Consumer Healthcare Market WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its wearable technology for treatment of chronic pain received 510(k) clearance (K140333) from the U.S. Food and Drug Administration (FDA) for
